Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Oil analyst Barney Gray discusses the latest from Tower, Coro, Colter, Reabold & United Watch Here

EXCLUSIVE: Oil analyst Barney Gray discusses the latest from Tower, Coro, Colter, Reabold & United
UPDATE: #COPL set timeline for Q2/Q3 Nigeria drilling programme


Motif Bio Share Chat (MTFB)



Share Price: 7.35Bid: 7.35Ask: 7.50Change: 0.00 (0.00%)No Movement on Motif Bio
Spread: 0.15Spread as %: 2.04%Open: 7.89High: 7.90Low: 7.20Yesterday’s Close: 7.35


Share Discussion for Motif Bio


Thread View

Please login or register to post a message on Share Chat.

Posts per page:

PrivateRyan
Posts: 410
Opinion:No Opinion
Price:7.90
RE: Some really interesting
Wed 23:53
Agreed. Well done techies ! In English as well not jargon ....lol
 
Birdseye
Posts: 1,567
Premium Chat Member
Opinion:No Opinion
Price:7.35
Some really interesting
Wed 23:45
Posts tonight, thanks to all.
Kettle
Posts: 113
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 23:40
Did I read somewhere that it begins working within 7 hours.
Jimzi
Posts: 10,926
Opinion:No Opinion
Price:7.90
RE: all talk about the treatment is
Wed 23:33
ATs only affect traders.
If your long, they have no effect - as in investment.
Good on you though, your the first trader to pop their head over the parapet today. I did say the’ll have you . .
marineville
Posts: 9,652
Opinion:No Opinion
Price:7.35
RE: all talk about the treatment is
Wed 23:22
deleted my reply as i realised i don't need to defend my position here. but you're right... i'll stick to watching the sp and try and get into the blue once and for all... i'll leave the raking over the coals to the bb.

good luck with your investment... and i hope the ATs treat you more kindly (though i'll obviously benefit too).
Jimzi
Posts: 10,926
Opinion:No Opinion
Price:7.90
RE: all talk about the treatment is
Wed 23:04
The autos clearly gave you a beating then !

Suggest you don’t read the bb for a while then. Most posters here are interested in the prospects and evidence of IC and not peeps who trade around the date they submit a request.
marineville
Posts: 9,652
Opinion:No Opinion
Price:7.35
all talk about the treatment is
Wed 22:49
pretty much irrelevant... insofar as, it is what it is.

while the outcome will be make or break, the only thing i'm interested in, right now, is to have the news that the revised documents have been sent... then to get the confirmation of a date for the meet... everything beyond that is just third in line... sounds obvious but i think we'll all breathe a sigh of relief when both those events are announced.

then i'll be happy to read the rest of the posts...
Jimzi
Posts: 10,926
Opinion:No Opinion
Price:7.90
Mentioned
Wed 22:48
Previously, theres so much self doubt and worrying cause it’s 7p. If it had adjusted to 20p as per the auction o Thursday opening , everyone would be positive.

Lesson in human behaviour and controlled thinking

MTFB is now the same mcap as IMM - failed P3- and is less than, not even started Phase 2 SCLP.

Very strong cases made for approval- autos really squeezing the traders - well , time for lookers and holders to decide.

It’s in play. During the 1508 to 1519 period of no trades, as commented on at the time, the dummy for volume was all over the place - varying from 6.85 to 8.738 but moving within this 11 min window with no trades . There’s your clue.

That’s why I study the book. To see the underlying forces.
Ian.B
Posts: 15,356
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 22:40
The drug is aimed at patients with renal issues so i dont see how it will impact. Vanc is widely used and iclaprim liver data is only a fraction different from vanc.

The difference is vanc causes renal injury (kidneys) whilst iclaprim does not -

26% of patients with Absssi have renal impairment = 936k patients a year x $3000 a course. - $2,8bn if iclaprim treated them all. Even if iclaprim treated 10% of the 936k renally impared = $279million p/a - 5% $1.4m pa etc etc.

The blackbox would relate to 2-3% who have raised liver enzymes.
Ivyspivey
Posts: 9,447
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 22:39
Got it from one of early MTFB presentations.
Iclaprim is bacterio cidal( means kills the bacteria) quickly with a fairly low dose rate .
Most other ABs are bacterio static( means stops development of bacteria rather than kill).
Important difference in helping prevent AMR(Antimicrobial Resistance) but there are several other reasons why Iclaprim has a low propensity to resistance including not being used in animals,being novel so a DHFR so structurally unrelated to other ABs,kills within cell etc
waccybaccy
Posts: 50
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 22:31
Ivyspivey, please can you say where you got that image from? It is pretty interesting.

I'm guessing "rapidly cidal" means it kills bacteria rapidly?

Thanks!
Numpity
Posts: 1
Opinion:No Opinion
Price:7.35
RE: Still confused...
Wed 22:23
It seems to me having kept up with posts over the last couple of months that there is little doubt it will eventually get approved. We can do nothing but sit back and hope it is approved with MTFB and we don’t get sold down the river.
PrivateRyan
Posts: 410
Opinion:No Opinion
Price:7.90
RE: Still confused...
Wed 22:17
Succinctly put. !
DayTrader67
Posts: 703
Opinion:No Opinion
Price:7.35
Still confused...
Wed 22:14
Still can't compute that we pass two Phase Three trials which had FDA input, had no liver toxicity concerns raised, no post NDA AdComm then non approval for liver toxicity concern!@!
hanibal
Posts: 411
Opinion:No Opinion
Price:7.90
RE: zachs
Wed 22:02
Wouldnt limit a black box warning our marketsuccess substantial? Sorry, have no knowledge, but it doesnt sound good. Blackbox as the word already says...
ColdFishPie
Posts: 256
Opinion:No Opinion
Price:7.90
RE: zachs
Wed 21:59
Seems like the fda approved linezold in the early 2000's.

Yes, that was the main highlight but they also have liver tox.
Ivyspivey
Posts: 9,447
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 21:56
CFP
The table is 3 years old and they highlighted main hazard of Linezolid as affecting diabetics
Ivyspivey
Posts: 9,447
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 21:54
CFP
Not seen their liver tox results specifically but coukd look at the SPC.
What you have to remember is if a drug like Linezolid or Vancomycin has been around for 30-40 years at the time of Approval the licensing regs were probably less rigorous.Yes they Wouk day have been subject to reviews but not the same level of scrutiny as newer drugs.
The point I am trying to make is that all drugs have side effects and if it is not liver it is renal like Vancomycin or CNS.
So is a balance between safety and efficacy and trade offs.
Remember the alternative for many of these patients is AKI ai(Acute Kidney Injury) in case of Vanco for so a temporary liver enzyme elevation is unlikely to be an exclusive reason not to use Iclaprim imo
ColdFishPie
Posts: 256
Opinion:No Opinion
Price:7.90
RE: zachs
Wed 21:53
Thanks ivy,

Yes, reading linezold wiki page it states that a medical team in australia have developed a process that includes regular liver testing and it also states that there is raised teansaminases with linezold also.

I presume its a lot lower and why mtfb have not included it in their table.

I would take a black box warning!
Tobias
Posts: 140
Opinion:No Opinion
Price:7.35
Thanks Ivy
Wed 21:45
.
Ivyspivey
Posts: 9,447
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 21:44
Look at Delafloxacin Approved earlier this year with a Black Box warning

https://baxdela.com/
Ivyspivey
Posts: 9,447
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 21:42
CFP
The main issues are effects diabetic patients.Also effects Seratonin so contravinducated in CNS treatments.

https://pbs.twimg.com/media/CsAeGZEWYAE2bYm.jpg
Tp23
Posts: 59
Opinion:No Opinion
Price:7.35
FDA Guidance for industry DILI
Wed 21:38
For those interested FDA guidance notes published in 2009
https://www.fda.gov/downloads/guidances/UCM174090.pdf
Ivyspivey
Posts: 9,447
Opinion:No Opinion
Price:7.35
RE: zachs
Wed 21:29
Hi Tobias,
Dont get hung up on metabolism mechanisms I just posted fir completeness .
Comment by my medical professional friend was

re. slow metabolism; i'm not sure that really holds. Iclaprim is metabolised by CYP3A4, which although demonstrates polymorphism, I don't think it leads to any particular clinically relevant alterations (But this could explain why some people metabolise it will and some don't). It's worth noting that even an inflammed liver with perhaps a 10-20fold rise in transaminases can still perform it's function perfectly well in many regards, and CYP3A4 is present in intestine too.

So important but if Iclaprim raised AST and ALT liver enzyme levels say above 3x normal in a very limited number of patients and returned to normal and did not cause any severe liver episodes then as my friend says even if they were raised 10-20x normal the liver can still function perfectly well.

Hope that helps
hopeabound
Posts: 6
Opinion:No Opinion
Price:7.35
Vox Markets article
Wed 21:26
Will further FDA discussions lead to approval for Motif Bio’s antibiotic Iclaprim?

**************************************/articles/will-further-fda-discussions-lead-to-approval-for-motif-bio-s-antibiotic-iclaprim--5df57ba/




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk









Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.